Products - Brain cancers | Topic | NICE

Showing 7 products

Date | Title

Product type: GuidanceRemove ‘Product type: Guidance’ filter
New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Suspected Cancer: recognition and referral (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
15 April 2026
Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407]
Status:
In development | In consultation
Programme:
Technology appraisal guidance
Consultation end date:
9 April 2026
Expected publication date:
29 April 2026
DCVax-L for treating glioblastoma [ID836]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Asunercept for treating glioblastoma [ID1301]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tovorafenib for treating relapsed or refractory paediatric low-grade glioma with BRAF fusion or rearrangement or BRAF V600 mutation in people 6 months and over [ID6557]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
LAM-561 with radiotherapy and temozolomide for treating IDH1 wild-type glioblastoma [ID4022]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC